These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 17995975)

  • 41. Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.
    Dratviman-Storobinsky O; Avraham-Lubin BCR; Hasanreisoglu M; Goldenberg-Cohen N
    Mol Vis; 2009 Nov; 15():2326-38. PubMed ID: 19936307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model.
    Sella R; Gal-Or O; Livny E; Dachbash M; Nisgav Y; Weinberger D; Livnat T; Bahar I
    Exp Eye Res; 2016 May; 146():224-232. PubMed ID: 27020759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
    Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
    J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
    Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
    Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization.
    Zhou AY; Bai YJ; Zhao M; Yu WZ; Li XX
    Ophthalmic Res; 2013; 50(3):180-6. PubMed ID: 24008241
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bevacizumab for corneal neovascularization.
    Jacobs DS; Lim M; Carrasquillo KG; Rosenthal P
    Ophthalmology; 2009 Mar; 116(3):592-3; author reply 593-4. PubMed ID: 19264217
    [No Abstract]   [Full Text] [Related]  

  • 47. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.
    Carrasco MA
    Cornea; 2008 Jul; 27(6):743-5. PubMed ID: 18580272
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of subconjunctival bevacizumab on corneal neovascularization and reepithelization 25 days after chemical burn].
    Mello GH; Lupion FG; Oliveira FM; Bude LR; Wasileweski D; Cavalcanti TC; Moreira H
    Arq Bras Oftalmol; 2011; 74(1):48-52. PubMed ID: 21670908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bevacizumab (avastin) for corneal neovascularization--corneal light shield soaked application.
    Mackenzie SE; Tucker WR; Poole TR
    Cornea; 2009 Feb; 28(2):246-7. PubMed ID: 19158579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of topical epigallocatechin gallate on corneal neovascularization in rabbits.
    Koh CH; Lee HS; Chung SK
    Cornea; 2014 May; 33(5):527-32. PubMed ID: 24608256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful single treatment with ziv-aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model.
    Gore A; Horwitz V; Cohen M; Gutman H; Cohen L; Gez R; Kadar T; Dachir S
    Exp Eye Res; 2018 Jun; 171():183-191. PubMed ID: 29548928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).
    Manzano RP; Peyman GA; Khan P; Carvounis PE; Kivilcim M; Ren M; Lake JC; Chévez-Barrios P
    Br J Ophthalmol; 2007 Jun; 91(6):804-7. PubMed ID: 17179168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.
    Li T; Hu A; Li S; Luo Y; Huang J; Yu H; Ma W; Pan J; Zhong Q; Yang J; Wu J; Tang S
    Mol Vis; 2011 Mar; 17():797-803. PubMed ID: 21528000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allograft survival enhancement using doxycycline in alkali-burned mouse corneas.
    Ling S; Li W; Liu L; Zhou H; Wang T; Ye H; Liang L; Yuan J
    Acta Ophthalmol; 2013 Aug; 91(5):e369-78. PubMed ID: 23387987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab.
    Lim M; Jacobs DS; Rosenthal P; Carrasquillo KG
    Semin Ophthalmol; 2009; 24(3):149-55. PubMed ID: 19437350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX; Bahar I; Levinger E; Rootman D
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model.
    Mello GR; Pizzolatti ML; Wasilewski D; Santhiago MR; Budel V; Moreira H
    Clinics (Sao Paulo); 2011; 66(8):1443-50. PubMed ID: 21915498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.
    Foroutan A; Fariba B; Pejman B; Mahmoud J; Khalil GF; Arash EA; Foroutan P
    Cornea; 2010 Nov; 29(11):1268-72. PubMed ID: 20802316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.
    Gerten G
    Cornea; 2008 Dec; 27(10):1195-9. PubMed ID: 19034142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.